Journal: medRxiv

Article Title: SARS-CoV-2 seroprevalence in Kaduna State, Nigeria during October/November 2021, following three waves of infection and immediately prior to detection of the Omicron variant

doi: 10.1101/2021.12.21.21268166

Figure Lengend Snippet: Daily new confirmed COVID-19 cases per million people in Nigeria, 7-day rolling average, 4 March 2020 to 30 November 2021. (Source: Our World In Data .)

Article Snippet: The CE-marked Biopanda COVID-19 IgM/IgG Rapid Test Kit was used to screen serum for antibodies, following the manufacturers’ instructions.

Techniques:

Journal: Frontiers in Immunology

Article Title: Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron

doi: 10.3389/fimmu.2023.1271209

Figure Lengend Snippet: Specific ancestral Spike (SW) IgG and IgG isotypes levels induced by homologous and heterologous vaccination schedule. (A) K18-hACE2 mice (n =7/group) were immunized on Days 0 and 14 with commercial vaccines mRNA1273 or AZD1222 plus a booster with formulations containing purified spike protein from ancestral (SW) or Delta (SD) SARS-CoV-2 variant on Day 60 delivered intramuscularly. (B) SW specific IgG levels induced by 2 dose primary series. Serum collected on Days 14 and 45 after the second dose was analyzed by ELISA. (C) SW specific IgG, (D) IgG1 and (E) IgG2c levels induced by 3-dose homologous and heterologous schemes. Sera from immunized and non-immunized were collected 14 Days after the 3 rd dose and analyzed by ELISA. Serum antibody levels are expressed as EC50 ± SD for each group. For statistical analysis, antibody levels were analyzed by a one-way ANOVA with Bonferroni’s multiple comparisons test. The * symbol indicate significant differences among immunized: ****p<0.0001, *** p<0.001, *p<0.05. The # symbol indicate significant differences between non-immunized and immunized animals: #### p <0,0001.

Article Snippet: RT-qPCR detection of SARS-CoV-2 was performed using kit LightMix® Modular SARS-CoV-2 (COVID19) E-gene, LightMix® Modular SARS-CoV (COVID19) RdRp (TIB MOLBIOL), and RNAsa P following the protocol developed by Dr. Corman et al. from the Institute of Virology, Charité, Berlin, Germany, by the World Health Organization ( https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf ) on a real time thermal cycler CFX96 (Biorad).

Techniques: Vaccines, Purification, Variant Assay, Enzyme-linked Immunosorbent Assay

Journal: Frontiers in Immunology

Article Title: Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron

doi: 10.3389/fimmu.2023.1271209

Figure Lengend Snippet: Homologus and heterologous immunization induces Ag-specific Th1 (IFN-γ)/Th17 (IL-17)/Th2 (IL-5). (A) K18-hACE2 mice (n =7/group) were immunized on Days 0 and 14 with commercial vaccines mRNA1273 or AZD1222 plus a booster with formulations containing purified spike protein from ancestral (SW) or Delta (SD) SARS-CoV-2 variant on Day 60 delivered intramuscularly. Mice were challenged 14 days after the 3 rd dose with SARS-CoV-2 Omicron BA.1 variant, 5 days after challenge mice were sacrificed and spleens were harvested. Levels of secreted IFN-γ (B) , IL-17 (C) and IL-5 (D) following splenocytes stimulation with medium or recombinant spike protein from W o D variants were determined by ELISA. Bars are means ± SEM of pg/ml. The * symbol indicate significant differences among immunized: ***p<0.001, **p<0.01, *p<0.05. The # symbol indicate significant differences between non-immunized and immunized animals: ####p<0.0001, ###p<0.001, ##p<0.01, #p<0.05.

Article Snippet: RT-qPCR detection of SARS-CoV-2 was performed using kit LightMix® Modular SARS-CoV-2 (COVID19) E-gene, LightMix® Modular SARS-CoV (COVID19) RdRp (TIB MOLBIOL), and RNAsa P following the protocol developed by Dr. Corman et al. from the Institute of Virology, Charité, Berlin, Germany, by the World Health Organization ( https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf ) on a real time thermal cycler CFX96 (Biorad).

Techniques: Vaccines, Purification, Variant Assay, Recombinant, Enzyme-linked Immunosorbent Assay

Journal: Frontiers in Immunology

Article Title: Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron

doi: 10.3389/fimmu.2023.1271209

Figure Lengend Snippet: Protection assay against Omicron BA.1 SARS-CoV-2 infection in the intranasal challenge mouse model. (A) K18-hACE2 mice (n =7/group) were immunized on Days 0 and 14 with commercial vaccines mRNA1273 or AZD1222 plus a booster with formulations containing purified spike protein from ancestral (SW) or Delta (SD) SARS-CoV-2 variant on Day 60 delivered intramuscularly. Mice were challenged 14 days after the 3 rd dose with SARS-CoV-2 Omicron BA.1 variant, 5 days after challenge mice were sacrificed and nasal washes and lungs were collected. (B, E) Changes in body weight were expressed as the percentage of body weight in comparison to day 0 (mean ± SEM.). Post-challenge weights were zoomed in for each treatment in the right part of the graph. (C, F) nasal and (D, G) lungs SARS-CoV-2 viral load after Omicron BA.1 challenge in animals vaccinated with schedules that contain mRNA-1273 (C, D) or AZD1222 (F, G) . Results are expressed as Log number Rdrp copies/ml nasal wash or as Log number Rdrp copies/mg lungs. One-way or Two-way ANOVA followed by Bonferroni post-test, were used for statistical analysis. ****p < 0.0001, ***p<0.001, **p < 0.01, *p<0.05.

Article Snippet: RT-qPCR detection of SARS-CoV-2 was performed using kit LightMix® Modular SARS-CoV-2 (COVID19) E-gene, LightMix® Modular SARS-CoV (COVID19) RdRp (TIB MOLBIOL), and RNAsa P following the protocol developed by Dr. Corman et al. from the Institute of Virology, Charité, Berlin, Germany, by the World Health Organization ( https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf ) on a real time thermal cycler CFX96 (Biorad).

Techniques: Infection, Vaccines, Purification, Variant Assay, Comparison

Journal: Frontiers in Immunology

Article Title: Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron

doi: 10.3389/fimmu.2023.1271209

Figure Lengend Snippet: Pathology score in lungs and brains for non-immunized and immunized animals. K18-hACE2 mice (n = 7/group) were immunized on Days 0 and 14 with commercial vaccines mRNA1273 or AZD1222, along with a booster containing purified spike protein from ancestral (SW) or Delta (SD) variants of SARS-CoV-2 on Day 60, administered intramuscularly. Fourteen days after the third dose, mice were challenged with the Omicron BA.1 variant of SARS-CoV-2. Five days after the challenge, mice were euthanized, and their lungs and brains were collected. An experienced pathologist performed blinded assessments of the lesions detected in the lungs (A) and brains (B) using a scale ranging from 0 to 3 (where 0 indicates no lesion, 1 mild, 2 moderate, and 3 severe). The data obtained are expressed as the percentage of animals that exhibited each degree of lesion.

Article Snippet: RT-qPCR detection of SARS-CoV-2 was performed using kit LightMix® Modular SARS-CoV-2 (COVID19) E-gene, LightMix® Modular SARS-CoV (COVID19) RdRp (TIB MOLBIOL), and RNAsa P following the protocol developed by Dr. Corman et al. from the Institute of Virology, Charité, Berlin, Germany, by the World Health Organization ( https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf ) on a real time thermal cycler CFX96 (Biorad).

Techniques: Vaccines, Purification, Variant Assay

Journal: Scientific Reports

Article Title: Network pharmacology approach to decipher signaling pathways associated with target proteins of NSAIDs against COVID-19

doi: 10.1038/s41598-021-88313-5

Figure Lengend Snippet: Protein protein interaction (PPI) networks with 26 nodes and 78 edges in NSAIDs against COVID-19 via STRING analysis. Node: the number of units; Edge: the number of interactions between the units.

Article Snippet: The protein–protein interaction network (PPI) between NSAIDs and COVID-19 targeted proteins were selected by STRING ( https://string-db.org/ ) and finally plotted by RStudio.

Techniques:

Journal: Oral Diseases

Article Title: Coronavirus disease 2019 (COVID‐19) vaccines: A concise review

doi: 10.1111/odi.13916

Figure Lengend Snippet: Key Advantages and disadvantages, and efficacy of approved major COVID‐19 vaccines (vaccines in late developmental phase are also shown, Classic platforms in Yellow and Next generation platforms in blue); Data form various sources

Article Snippet: VI (Next generation) , DNA Vaccines , (See also Figure ) , Delivers SARS‐CoV−2 DNA genes into cells, with the help of a plasmid (“a jumping gene” found in bacteria) to provoke an immune response , INO−4800 (International Vaccine Institute; Inovio Pharmaceuticals), Symvivo, Canada ‐COVID19 (AnGes, Inc.); GX−19 (Genexine, Inc.) , Expresses S (spike) protein , Veterinary infections (None so far approved for COVID−19) , Nil.

Techniques: Vaccines, Virus, Infection, Immunopeptidomics, Plasmid Preparation, Full Display Name

Journal: Oral Diseases

Article Title: Coronavirus disease 2019 (COVID‐19) vaccines: A concise review

doi: 10.1111/odi.13916

Figure Lengend Snippet: Manufacturing platforms, immunization attributes and examples of different COVID‐19 vaccines (either currently available or in developmental pipeline; minor platforms are not shown)

Article Snippet: VI (Next generation) , DNA Vaccines , (See also Figure ) , Delivers SARS‐CoV−2 DNA genes into cells, with the help of a plasmid (“a jumping gene” found in bacteria) to provoke an immune response , INO−4800 (International Vaccine Institute; Inovio Pharmaceuticals), Symvivo, Canada ‐COVID19 (AnGes, Inc.); GX−19 (Genexine, Inc.) , Expresses S (spike) protein , Veterinary infections (None so far approved for COVID−19) , Nil.

Techniques: Vaccines, Virus, Variant Assay, Recombinant, Binding Assay, Plasmid Preparation, Bacteria